Johnson & Johnson Vaccine Protects Against Delta Variant, Company Reports

The vaccine also produced long-lasting immune responses, researchers said. Booster shots seem unnecessary, at least for now.

Three Studies, One Result: Vaccines Point the Way Out of the Pandemic

New scientific research underscores the effectiveness of vaccines and their versatility in the fight against the coronavirus.

New Therapy for Aggressive Prostate Cancer Improves Survival

The experimental treatment relies on radioactive molecules that seek out tumor cells, a strategy that may be useful against other cancers.

Why More People Are Getting Two Different Coronavirus Vaccines

Several countries are allowing mix-and-match inoculation, which scientists hope will have benefits, and Chancellor Angela Merkel of Germany is among those to get it.

Many Alzheimer’s Experts Say Use of Aduhelm Should Be Sharply Limited

Even those who supported the F.D.A.’s approval of the controversial new drug said authorizing it for anyone with Alzheimer’s disease was much too broad.

Wondering if the Vaccine Worked? Get the Right Test, at the Right Time.

Scientists generally recommend against antibody testing after vaccination. But for some people, it makes sense.

Wondering if the Vaccine Worked? Get the Right Test, at the Right Time.

Scientists generally recommend against antibody testing after vaccination. But for some people, it makes sense.

A Pill to Treat Covid-19? The U.S. Is Betting on It.

A new $3.2 billion program will support the development of antiviral pills, which could start arriving by the end of this year.

CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial.

The results were a blow to hopes that the vaccine could help meet the world’s urgent need. “This is pretty devastating” for the company, one expert said.

Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine

The company’s large U.S. trial found an efficacy rate of about 90 percent. But at this point, the nation is awash in other shots.

Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug

The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.

Opinion | TED Talks Won’t Treat Your Depression

A myopic but seductive worldview has caught on among many influential people — and it might be hindering our ability to solve real-world problems.

¿Las vacunas contra la COVID-19 van a necesitar refuerzos?

Los científicos están haciendo diversas preguntas sobre las inyecciones de refuerzo, pero aún no tienen tantas respuestas. Esto es lo que saben hasta ahora.

Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense

Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.

F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works

Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some experts say there’s not enough evidence it can address cognitive symptoms.

F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works

Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some experts say there’s not enough evidence it can address cognitive symptoms.

We’ll Probably Need Booster Shots for Covid-19. But When? And Which Ones?

Scientists are asking a lot of questions about Covid-19 booster shots, but they don’t yet have many answers. Here’s what they know so far.

Alzheimer’s Drug Poses a Dilemma for the F.D.A.

If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works.

Opinion | People Want an Alzheimer’s Drug. This Isn’t the One.

An F.D.A. sign-off for aducanumab would make finding a good treatment harder.

Moderna Vaccine Highly Effective in Adolescents, Company Says

The U.S., which has a surplus of vaccines, could soon have two options for teens while many countries face shortages.